Threat Intelligence
Biomemory Unveils DNA Shield, Its First Commercial Product on a Molecular IT Platform
Dark Reading · 17 Oct 2026
Key Takeaway
Wait for independent technical details and evidence before considering any new, unfamiliar security product, and judge it against your actual business risks.
Biomemory has launched DNA Shield, the first commercial product built on its Molecular IT platform, according to Dark Reading.
The launch comes after two earlier developments this year: the acquisition of catalog's assets, and the appointment of Laurent Guengant as CEO.
The summary available does not explain what DNA Shield does, who it is for, or how it is priced or delivered. Until Biomemory publishes more detail, businesses should treat this as an early announcement rather than a proven security option.